Artiva Biotherapeutics, Inc. Common Stock - Asset Resilience Ratio
Artiva Biotherapeutics, Inc. Common Stock (ARTV) has an Asset Resilience Ratio of 65.47% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Artiva Biotherapeutics, Inc. Common Stoc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2024)
This chart shows how Artiva Biotherapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Artiva Biotherapeutics, Inc. Common Stoc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Artiva Biotherapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Artiva Biotherapeutics, Inc. Common Stoc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $97.46 Million | 65.47% |
| Total Liquid Assets | $97.46 Million | 65.47% |
Asset Resilience Insights
- Very High Liquidity: Artiva Biotherapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 65.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Artiva Biotherapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Artiva Biotherapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Artiva Biotherapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual Asset Resilience Ratio data for Artiva Biotherapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 69.28% | $145.19 Million | $209.58 Million | +46.95pp |
| 2023-12-31 | 22.33% | $23.47 Million | $105.11 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $133.05 Million | -- |
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus n… Read more